1 Jiang X,Tang H,Chen T.Epidemiology of gynecologic cancers in China[J].J Gynecol Oncol,2018,29(1):e7. 2 Stewart C,Ralyea C,Lockwood S.Ovarian cancer:an integrated review[J].Semin Oncol Nurs,2019,35(2):151-156. 3 Porter RL,Matulonis UA.Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer[J].Expert Rev Anticancer Ther,2023,23(8):783-796. 4 Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263. 5 Han X,Wang Z,Huang D,et al.Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020[J].BMC Womens Health,2022,22(1):504. 6 GBD 2021 Diseases and Injuries Collaborators.Global incidence,prevalence,years lived with disability(YLDs),disability-adjusted life-years(DALYs),and healthy life expectancy(HALE)for 371 diseases and injuries in 204 countries and territories and 811 subnational locations,1990-2021:a systematic analysis for the Global Burden of Disease Study 2021[J].Lancet,2024,403(10440):2133-2161. 7 Rosenberg PS,Check DP,Anderson WF.A web tool for age-period-cohort analysis of cancer incidence and mortality rates[J].Cancer Epidemiol Biomarkers Prev,2014,23(11):2296-2302. 8 Melaku YA,Gill TK,Appleton SL,et al.Sociodemographic,lifestyle and metabolic predictors of all-cause mortality in a cohort of community-dwelling population:an 18-year follow-up of the North West Adelaide Health Study[J].BMJ Open,2019,9(8):e030079. 9 Kim HJ,Chen HS,Midthune D,et al.Data-driven choice of a model selection method in joinpoint regression[J].J Appl Stat,2022,50(9):1992-2013. 10 Gaona-Luviano P,Medina-Gaona LA,Magaña-Pérez K.Epidemiology of ovarian cancer[J].Chin Clin Oncol,2020,9(4):47. 11 Webb PM,Jordan SJ.Global epidemiology of epithelial ovarian cancer[J].Nat Rev Clin Oncol,2024,21(5):389-400. 12 Cabasag CJ,Fagan PJ,Ferlay J,et al.Ovarian cancer today and tomorrow:a global assessment by world region and Human Development Index using GLOBOCAN 2020[J].Int J Cancer,2022,151(9):1535-1541. 13 Sullivan SD,Sarrel PM,Nelson LM.Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause[J].Fertil Steril,2016,106(7):1588-1599. 14 Gray SW,O′Grady C,Karp L,et al.Risk information exposure and direct-to-consumer genetic testing for BRCA mutations among women with a personal or family history of breast or ovarian cancer[J].Cancer Epidemiol Biomarkers rev,2009,18(4):1303-1311. 15 Abadir AM,Lang A,Klein T,et al.Influence of qualitative research on women′s health screening guidelines[J].Am J Obstet Gynecol,2014,210(1):44. 16 Vogell A,Evans ML.Cancer screening in women[J].Obstet Gynecol Clin North Am,2019,46(3):485-499. |